Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
McKinsey
Dow
Baxter
Harvard Business School

Last Updated: June 9, 2023

Details for New Drug Application (NDA): 022526


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 022526 describes ADDYI, which is a drug marketed by Sprout Pharms and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the ADDYI profile page.

The generic ingredient in ADDYI is flibanserin. One supplier is listed for this compound. Additional details are available on the flibanserin profile page.
Summary for 022526
Tradename:ADDYI
Applicant:Sprout Pharms
Ingredient:flibanserin
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 022526
Mechanism of ActionP-Glycoprotein Inhibitors
Suppliers and Packaging for NDA: 022526
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADDYI flibanserin TABLET;ORAL 022526 NDA Sprout Pharmaceuticals, Inc. 58604-214 58604-214-30 1 BOTTLE in 1 CARTON (58604-214-30) / 30 TABLET, FILM COATED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Aug 18, 2015TE:RLD:Yes
Patent:⤷  Try a TrialPatent Expiration:May 9, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
Patent:⤷  Try a TrialPatent Expiration:Aug 1, 2022Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Try a TrialPatent Expiration:May 9, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

Expired US Patents for NDA 022526

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 ⤷  Try a Trial ⤷  Try a Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 ⤷  Try a Trial ⤷  Try a Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Express Scripts
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.